Please assess the completion status of the following clinical trial:

Trial Title: Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. active macula-involved polypoidal lesions evidenced by ICGA;~2. greatest linear dimension of 5400 μm or less assessed by ICGA;~3. follow-up of at least 12 months.~Exclusion Criteria:~1. any other ocular disease, such as ocular trauma, glaucoma, uveitis, diabetic retinopathy, angioid streaks, pathologic myopia, or presumed ocular histoplasmosis syndrome;~2. any systemic contraindication to the PDT, IVR, sodium fluorescein, or indocyanine green dyes;~3. any severe uncontrolled systemic disease, such as uncontrolled hypertention, coronary heart disease, liver failure, or kidney failure.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- photodynamic therapy (Type: EXPERIMENTAL): Participants will be given the standard verteporfin photodynamic therapy at baseline followed by additional standard verteporfin PDT as needed (every three months)(namely 1+PRN regimen).
- intravitreal ranibizumab (Type: EXPERIMENTAL): Participants will receive the intravitreal ranibizumab treatment (0.05mg) at baseline and additional intravitreal ranibizumab will be given to the participants when necessary (every month) (namely 1+PRN regimen).
- combination therapy of PDT and IVR (Type: EXPERIMENTAL): Participants will be given the standard verteporfin photodynamic therapy followed by intravitreal ranibizumab (0.05mg) 72h after the standard verteporfin PDT treatment at baseline. Additional verteporfin photodynamic therapy and intravitreal ranibizumab (0.05mg) will be given to the participants when necessary (every month)(namely 1+PRN regimen).

Based on this trial design, predict the completion outcome and termination type (if applicable).